Antifungal efficacy of amphotericin B encapsulated fibrin microsphere for treating Cryptococcus neoformans infection in Swiss albino mice.
A natural and biocompatible fibrin microsphere is one of the most promising dual delivery vehicle as compared to other traditionally designed delivery modalities. It represents sustained delivery of encapsulated drug and is easily biodegradable in the blood circulation. In the present study, we evaluated the systemic augmentation of the antifungal activity of amphotericin B loaded in fibrin microsphere (AMB-fibrin microsphere) against cryptococcosis in Swiss albino mice. Mice infected with Cryptococcus neoformans were treated with 0.5mg/kg AMB-fibrin microsphere that was given alternately for 7 days. The antifungal potential of AMB-fibrin microsphere was assessed on the basis of reduction of cfu count in the systemic circulation and various vital organs of infected mice. The formulation was found to be highly effective in reducing intracellular pathogen from the experimental animals where fibrin microsphere significantly controlled the release of amphotericin B for longer time duration. The AMB-fibrin microsphere chemotherapy was significantly more effective than free amphotericin B in reducing the fungal burden and showed better survival efficacy (p<0.05). The current study demonstrating the use of novel amphotericin B loaded fibrin microsphere not only imparts protection to the encapsulated amphotericin B but also offers an effective strategy to decrease the drug associated toxicities.
King Saud University, College of Pharmacy, Department of Pharmaceutical Chemistry, Pharmaceutical Biotechnology Laboratory, Riyadh, Saudi Arabia. Electronic address: azmatbiotech@gmail.com.
Azmat Ali
AA
Khan
Aligarh Muslim University, Department of Zoology, Section of Genetics, Aligarh, India.
Mumtaz
M
Jabeen
King Saud University, College of Pharmacy, Department of Pharmaceutical Chemistry, Pharmaceutical Biotechnology Laboratory, Riyadh, Saudi Arabia.
Amer M
AM
Alanazi
King Saud University, College of Pharmacy, Department of Pharmaceutics, Riyadh, Saudi Arabia.
Abdul Arif
AA
Khan
D000666:Amphotericin B / Q000008:administration & dosage*; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage*; D003453:Cryptococcosis / Q000188:drug therapy*; D003455:Cryptococcus neoformans; D004195:Disease Models, Animal; D005260:Female; D005337:Fibrin / Q000008:administration & dosage*; D051379:Mice; D008863:Microspheres; D013997:Time Factors
D000935:Antifungal Agents; D000666:Amphotericin B; D005337:Fibrin
Amphotericin B; Cryptococcosis; Cryptococcus neoformans; Fibrin microsphere